Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kavanagh

Showing results (651-660 of 764) with videos related to

Pageof 77
Sort By:
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1996
Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinomaR S Freedman, J A Gibbons, M Giedlin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerI Vergote, N Finkler, J del Campo, et al.
Cancer|May 1, 1986
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatinD M Gershenson, J J Kavanagh, L J Copeland, et al.
Cancer Biology & Therapy|August 17, 2012
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3Siqing Fu, Yanfang Li, Jie Huang, et al.
Journal of Immunological Methods|August 23, 2001
Simultaneous analysis of surface marker expression and cell cycle progression in human peripheral blood mononuclear cellsM T Rosato, A J Jabbour, R A Ponce, et al.
Molecular Pharmacology|October 20, 2001
Enhanced acetaminophen hepatotoxicity in transgenic mice overexpressing BCL-2M L Adams, R H Pierce, M E Vail, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Docetaxel for patients with paclitaxel-resistant Müllerian carcinomaC F Verschraegen, T Sittisomwong, A P Kudelka, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 27, 2005
Profiling of differentially expressed genes in human uterine leiomyomasE-J Lee, G Kong, S-H Lee, et al.
Pigment Cell Research|July 11, 2006
Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytesJennifer E Hauser, Ana Luisa Kadekaro, Renny J Kavanagh, et al.
Anti-Cancer Drugs|March 10, 1998
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitorC F Verschraegen, E A Natelson, B C Giovanella, et al.
Pageof 77

Showing results (651-660 of 764) with videos related to

Sort By:
Pageof 77
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|November 1, 1996
Immunopharmacology and cytokine production of a low-dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinomaR S Freedman, J A Gibbons, M Giedlin, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2009
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerI Vergote, N Finkler, J del Campo, et al.
Cancer|May 1, 1986
Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vinblastine, bleomycin, and cisplatinD M Gershenson, J J Kavanagh, L J Copeland, et al.
Cancer Biology & Therapy|August 17, 2012
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3Siqing Fu, Yanfang Li, Jie Huang, et al.
Journal of Immunological Methods|August 23, 2001
Simultaneous analysis of surface marker expression and cell cycle progression in human peripheral blood mononuclear cellsM T Rosato, A J Jabbour, R A Ponce, et al.
Molecular Pharmacology|October 20, 2001
Enhanced acetaminophen hepatotoxicity in transgenic mice overexpressing BCL-2M L Adams, R H Pierce, M E Vail, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Docetaxel for patients with paclitaxel-resistant Müllerian carcinomaC F Verschraegen, T Sittisomwong, A P Kudelka, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 27, 2005
Profiling of differentially expressed genes in human uterine leiomyomasE-J Lee, G Kong, S-H Lee, et al.
Pigment Cell Research|July 11, 2006
Melanin content and MC1R function independently affect UVR-induced DNA damage in cultured human melanocytesJennifer E Hauser, Ana Luisa Kadekaro, Renny J Kavanagh, et al.
Anti-Cancer Drugs|March 10, 1998
A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitorC F Verschraegen, E A Natelson, B C Giovanella, et al.
Pageof 77